Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients – Healio

Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant and hematopoietic-cell transplant recipients, according to a study published in Open Forum Infectious Diseases.
“Solid-organ and…

Click here to view the original article.